PATHOGENESIS, ACTUAL ASPECTS OF PREVENTION AND TREATMENT OF THE ANTIBIOTIC-ASSOCIATED DIARRHOEA

The article provides an overview of current Russian and foreign literature devoted to the problem of pathogenesis, and of the treatment and prevention of antibiotic-associated diarrhea. Antibiotic-associated diarrhea is one of the most relevant aspects of modern drug therapy in due to the frequent prescription of antibacterial agents. Antibiotic-associated diarrhea (according to WHO) is defined as the presence of three or more episodes of an unformed stool for two or more consecutive days that occurred during or after the end of antibiotic therapy. The risk of developing this disorder is highest when using aminopenicillins, as well as their combinations with clavulanic acid, cephalosporins, clindamycin. Despite the presence of a common etiologic factor — the intake of antibacterial agents, the immediate causes and mechanisms of antibiotic-associated diarrhea development in patients may be different. The article describes the main issues of the etiology and pathogenesis of this pathology, the risk factors for the development of antibiotic-associated diarrhea are named, that allows to predict this complication in certain categories of patients. Тhe virulence factors of Clostridium difficile, Klebsiella oxytoca, Candida spp. and the clinical manifestations associated with their effects are highlighted. The clinical variants of this disease are described: 1) pseudomembranous colitis; 2) segmental hemorrhagic colitis; 3) “mild illness”. Contemporary literature data on the possibilities of prevention, as well as effective methods of treatment of antibiotic-associated diarrhea, are presented. For the treatment and prevention of all clinical forms of antibiotic-associated diarrhea, most authors suggest the use of drugs that make up the deficiency of normal intestinal microbiota — probiotics and prebiotics. The problem of the benefits of adjuvant therapy with probiotics during the course of antibiotics for the prevention of antibiotic-associated diarrhea remains controversial, the effectiveness and safety of the use of various probiotic cultures for this purpose is being studied. The information presented in this review is intended to target physicians to the rational use of antibacterial agents, and to early diagnosis of their most frequent side effect, antibiotic-associated diarrhea.

1. Wistrоm J., Norrby S.R., Myhre E.B., Eriksonn S., Grandström G., Lagergren L. et al. Frequency of antibiotic associated diarrhoea in 2462 antibiotic treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001; 47: 43 50.

2. Barbut F., Meynard J.L., Guiguet M., Avesani V., Bochet M.V., Meyohas M.C. et al. Clostridium difficile associated diarrhea in HIV infected patients: epidemiology and risk factors. J Acq Immun Def Synd. 1997; 16: 176 81.

3. McFarland L.V., Surawicz C.M., Stamm W.E. Risk factors for Clostridium difficile carriage and C. difficile associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990; 162: 678 84.

4. Bartlett J.G. Antibiotic-associated diarrhea. N. Engl. J. Med. 2002; 346(5): 334-339.

5. Ivashkin V.T., Yushchuk N.D., Mayev I.V., Lapina T.L., Poluektova Ye.A., Shifrin O.S., Tertychny A.S., Trukhmanov A.S., Sheptulin A.A., Baranskaya Ye.K., Lyashenko O.S., Ivashkin K.V. Diagnostics and treatment of Clostridium difficile-associated disease: Guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol 2016; 26(5). P. 56 — 65. [In Russian].

6. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998; 40: 1 15.

7. Garey K.W., Sethi S., Yadav Y., DuPont H.L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008; 70: 298–304. doi: 10.1016/j.jhin.2008.08.012.

8. Deshpande A., Pasupuleti V., Thota P., Pant C., Rolston D.D., Hernandez A.V., Donskey C.J., Fraser T.G. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015 Apr; 36(4): 452-60. doi: 10.1017/ice.2014.88. Epub 2015 Jan 28.

9. Furuya-Kanamori L., Wangdi K., Yakob L., McKenzie S.J., Doi S.A., Clark J. et al. 25-Hydroxyvitamin D concentrations and Clostridium difficile infection: a meta-analysis. JPEN J Parenter Enteral Nutr. 2015; 23: 0148607115623457.

10. Abou Chakra C.N., Pepin J., Sirard S., Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One. 2014; 9: e98400. doi: 10.1371/journal.pone.0098400.

11. Korneyeva O.N., Ivashkin V.T. Antibiotic-associated colitis: pathomorphology, clinical presentation, treatment. Ross. z. gastroenterol. gepatol. koloproktol. 2007; 3: 65 — 70 [In Russian].

12. Hogenauer C., Hammer H.F., Krejs G.J., Reisinge, E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin. Infect. Dis. 1998; 27: 702-710.

13. Dobbins W.O., Herrero B.A., Mansbach C.M. Morphologic alterations associated with neomycin induced malabsorption. Am. J. Med. Sci.— 1968. — Suppl. 225. — P. 63-77.

14. Denève C., Janoir C., Poilane I., Fantinato C., Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents. 2009 Mar; 33; Suppl 1: S24-8. doi: 10.1016/S09248579(09)70012-3.

15. Gonzalez A., Stombaugh J., Lozupone C., Turnbaugh P.J., Gordon J.I., Knight R. The mind-body-microbial continuum. Dialogues Clin Neurosci. 2011; 13(1): 55-62.

16. Hogenauer C., Langner C., Krause R., Gerstgrasser N., Krejs G.J., Hinterleitner T.A. Antibiotic-associated segmental hemorrhagic colitis: clinical features, and influence of Klebsiella oxytoca in its patogenesis. Abstracts of 12 UEGW, Gut. 2004; 53 (Suppl VI): A135.

17. Shevyakov M.A. Antibiotic-assotiated diarrhoea and intestinal candidiasis: the capabilities of treatment and prevention. Antibiotics and chemotherapy. 2004; 49(10): 26-29. [In Russian].

18. McFarland L.V., 2010 Probiotics and Diarrhea. Ann. Nutr. Metab. 2010; 57 (suppl. 1): 10-11.

19. Koning C., Jonkers D., Stobberingh E., Stockbrugger R. The effect of a multispecies probiotic on the intestinal flora and bowel habits in healthy volunteers treated with amoxicillin. Abstracts of 12 UEGW, Gut. 2004; 53 (Suppl VI) A207.

20. Saade E., Deshpande A., Kundrapu S. et al. Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection. Current medical research and opinion. 2013 Aug; 29(8): 985–988.

21. Pancheva-Dimitrova R.Z., Georgieva-Shakola M., Tzaneva V. Probiotics and antibiotic-associated diarrhea in children. Abstracts of 12 UEGW, Gut. — 2004; 53 (Suppl VI), A137.

22. Butler C.C., Duncan D., Hood K. Does taking probiotics routinely with antibiotics prevent antibiotic associated diarrhoea? BMJ. 2012; 344: e682.

23. Spinler Jennifer K., Ross Caná L., Savidge Tor C. Probiotics as adjunctive therapy for preventing Clostridium difficile infection — What are we waiting for? Anaerobe. 2016 Oct; 41: 51–57.

24. Ollech J.E., Shen N.T., Crawford C.V., Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol. 2016 Feb; 30(1): 111-8.

25. Mills J.P., Rao K., Young V.B. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol. 2018 Jan; 34(1): 3-10.

26. Evans C.T., Johnson S. Prevention of Clostridium difficile Infection with Probiotics. Clin Infect Dis. 2015 May 15; 60 Suppl 2: S122-8.

27. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., Simon M.S., Evans A.T. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium Difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017 Jun; 152(8): 18891900.e9.

28. McFarland L.V. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. Benef Microbes. 2015; 6(2): 189-94.

29. Konturek P.C., Koziel J., Dieterich W., Haziri D., Wirtz S., Glowczyk I., Konturek K., Neurath M.F., Zopf Y. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J Physiol Pharmacol. 2016 Dec; 67(6): 859-866.

30. Webb B.J., Brunner A., Ford C.D., Gazdik M.A., Petersen F.B., Hoda D. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2016 Aug; 18(4): 628-33.

31. Kelly C.R., de Leon L., Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012 Feb; 46(2): 145-9.

32. Juszczuk K., Grudlewska K., Mikucka A., Gospodarek E. Fecal microbiota transplantation — methods of treatment of recurrent Clostridium difficile infections and other diseases. Postepy Hig Med Dosw (Online). 2017 Mar 27; 71(0): 220-226.